PF07104091 New

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP42948CAS No. ：2460249-19-6Purity：98%

Size	Price	Stock	Quotation Inquiry
5.00 mg	Get quote	In-stock	Quotation Inquiry
10.00 mg	Get quote	In-stock	Quotation Inquiry
50.00 mg	Get quote	In-stock	Quotation Inquiry

Get Quotation Now

Tel: 0086-17754423994 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	2460249-19-6	Cat. No.	BCP42948
Name	PF07104091
Synonyms	PF 07104091; PF07104091; PF-7104091; PF 7104091; PF7104091;
SMILES	O=C(C1=CC(COC)=NN1C)NC2=NNC([C@](CC3)([H])C[C@@H]3OC(NC(C)C)=O)=C2
Chemical Name
Formula	C19H28N6O4	M. Wt	404.46
Purity	98%	Storage	Store at 4-8°C
Description	PF-07104091 is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, CDK2 inhibitor PF-07104091 selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.